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Since its description by Macaulay (1968), lymphomatoid
papulosis (LyP) has been recognized as a clinically benign
but often recurrent condition. The skin of patients is
characterized by the presence of self-healing, ulcerative,
and polymorphous papular/nodular and ulcerative lesions.
Recent reports propose that LyP is one of several
lymphoproliferative disorders that are characterized by the
expression of CD30 on atypical lymphocytes. The spectrum
of CD30þ lymphoproliferative diseases, which include
CD30þ anaplastic large cell lymphoma (ALCL) as well as
LyP, constitutes the second most common lymphomas
among the cutaneous T cell lymphomas (Willemze and
Beljaards, 1993). Despite its characterization as a benign
disorder, LyP has been associated with mycosis fungoides,
Hodgkin’s disease, and non-Hodgkin’s lymphoma in up to
19% of cases both before and after presentation with LyP
(Bekkenk et al, 2000).
Kadin (1990) and Willemze (Willemze and Beljaards,
1993) proposed that LyP and CD30þ ALCL represent polar
ends of a ‘‘spectrum’’ of CD30þ lymphoproliferative
diseases. Although it is clear that CD30 is, to variable
degrees, expressed by these skin entities, and, therefore,
serves as a diagnostic marker, there is emerging evidence
to suggest that CD30 may play a direct biological role in
the clinical behavior of these diseases, particularly in the
spontaneous regression observed with LyP. Interestingly,
triggering of CD30 via its endogenous ligand, CD30 ligand
(CD30L), may actually stimulate proliferation in the malig-
nant forms of CD30þ lymphoproliferative disease. Depend-
ing on the cell type tested and on the context of testing (i.e.,
in vivo vs in vitro), however, the regulation of cell survival and
proliferation via CD30 is indeed complex. In this brief
overview, we will evaluate recent data in an attempt to
address the molecular pathways by which CD30 can act as
both a negative and positive growth regulator, depending on
the cell type expressing it. Moreover, we will discuss new
therapies that specifically target the CD30 molecule in the
potential treatment of these disorders.
CD30 is a member of the TNF receptor superfamily,
whose members help regulate life and death decisions
within cells. Although little or no CD30 is detectable in
resting T and B cells, except within parafollicular areas of
the lymph node, its expression is enhanced on the surface
of activated or virus-infected T and B cells and on
neoplastic cells of both Hodgkin’s and non-Hodgkin’s
lymphomas. Except for expression on decidua and en-
dometrial cells with decidual change, it does not appear to
be expressed by non-lymphoid cells (Horie and Watanabe,
1998). The bulk of evidence suggests that engagement of
CD30 initiates a negative growth signal leading to apoptosis
in many cases. Structurally, CD30 does not possess the
death domains found in CD95/Fas and TNF receptor 1. The
CD30 cytoplasmic tail, however, binds to TNFR-associated
factor (TRAF) family members: TRAF1, TRAF2, and TRAF3,
but only TRAF1 and TRAF2 mediate the induction of NF-kB
(Duckett et al, 1997). TRAF2 binds to the CD30 cytoplasmic
tail, which then results in the rapid proteolytic degradation
of TRAF2 and the associated protein TRAF1. Thus, CD30
may, under some circumstances, limit its own ability to
transmit survival signals through NF-kB by inducing the
destruction of required downstream messengers (Fig 1).
Depletion of TRAF1 and TRAF2 following CD30 engage-
ment renders target cells more susceptible to apoptosis
triggered through other members of the TNF receptor family
(Duckett and Thompson, 1997). Moreover, because abnor-
mal cells found in LyP and ALCL apparently still express Fas
(Levi et al, 2000), it is possible that cells depleted of TRAF1
and TRAF2 by CD30 activation are also more susceptible to
Fas-mediated apoptosis (Fig 1). Thus, in LyP, depletion of
TRAFs following CD30 engagement may make the abnor-
mal T cell involved susceptible to apoptosis triggered by a
variety of mechanisms, including Fas activation.
The transition from LyP to systemic ALCL correlates with
the loss of responsiveness of lymphoma cells to CD30-
mediated signals. Levi et al (2000) examined the effects of
CD30 and Fas activation among three cell lines derived from
patients who had progressed from LyP to frank systemic
anaplastic large cell lymphoma. Incubation of these cells
lines with an agonistic anti-CD30 mAb resulted in modest
increases in proliferation in two out of the three cell lines. Of
note, all three lines showed NF-kB activation. Prior expre-
ssion of NF-kB may be a key in determining the fate of the
cell following CD30 activation. In the presence of NF-kB,
CD30þ lymphoma may undergo proliferation. This appears
to be the case with the malignant B cells found in Hodgkin’s
disease. Thus, depending on the availability of down-stream
effector molecules, a given cell may undergo proliferation
(via NF-kB) or apoptosis (Duckett et al, 1997) (Fig 1).
Abbreviations: ALCL, anaplastic large cell lymphoma; CD30L,
CD30 ligand; LyP, lymphomatoid papulosis; TGF, transforming
growth factor; TRAF, TNFR-associated factor
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The cellular effects of CD30 activation depend in part on
the type of cell expressing CD30. Indeed, a major limitation
to most of the studies cited herein is the almost exclusive
use of propagated cell lines that express CD30 rather than
fresh cells from patients. Bearing these limitations in mind,
activation of CD30 in ALCL-derived cell lines generally leads
to apoptosis of these cells and impairment of these cells to
initiate NF-kB-dependent survival pathways (Mir et al,
2000). Some investigators (Levi et al, 2000, 2001) have
observed decreased proliferation, but no evidence of
apoptosis, in the same lines used by Mir et al. Differences
in results could well be associated with the method by
which cross-linking of CD30 was achieved. Under condi-
tions in which antibodies were immobilized on a plastic
substrate (and thus are present at much higher surface
densities) rather than added in a soluble form, apoptosis
appears to be the predominant outcome (Mir et al, 2000). In
contrast to ALCL cell lines, cell lines derived from Hodgkin’s
disease (HD) samples expressed NF-kB constitutively and
underwent proliferation in response to CD30 triggering (Mir
et al, 2000). Thus, the constitutive expression of NF-kB may
be a key regulatory difference between the malignant cells
of HD and those of ALCL.
If triggering via CD30 is a prerequisite for regression of
LyP lesions, what is the source of the in vivo CD30L? Mori et
al. have observed frequent expression of CD30L in
regressing LyP lesions but rarely in growing LyP lesions.
Interestingly, CD30L was expressed mostly by the CD30þ
neoplastic cells in most cases, suggesting a form of
negative self-regulation, either in a paracrine or autocrine
fashion. Furthermore, small lymphocytes were also found to
express CD30L in selected cases (Mori et al, 1999). Other
leukocytes, including eosinophils, which have been fre-
quently observed in the mixed inflammatory infiltrate of LyP
lesions, may also serve as sources for CD30L.
Regression in LyP may also be regulated by receptors
other than CD30. Transforming growth factor-(TGF)-b, a
potent inhibitor of proliferation in many normal epithelial and
hematopoietic cells, has been detected in regressing LyP
lesions as well as LyP-associated lymphomas (Kadin et al,
2001). TGF-b inhibited the growth of CD30þ cell lines
derived from patients with LyP in regression, whereas TGF-
b failed to inhibit the growth of two related cell lines that
were obtained from non-regressing, progressive tumors
derived from the same patient (Kadin et al, 2001). Molecular
analysis of TGF-b receptors revealed that these two cell
lines had decreased levels of type I and II TGF-b receptors
and a loss-of-function mutation in TbR-II that could account
for the lack of responsiveness to TGF-b (Kadin et al, 1994;
Knaus et al, 1996) (Fig 1).
Interestingly, TGF-b receptors, like CD30, can initiate
both anti-tumor as well as pro-oncogenic signals depending
on the context of stimulation (Roberts and Wakefield, 2003).
In the case of TGF-b, some have proposed that the growth-
inhibitory role of TGF-b occurs when the affected cells are
exposed to TGF-b for extended periods of time, whereas
the pro-oncogenic effects occur after shorter exposure to
TGF-b, which results in the expression of ‘‘early’’ TGF-b-
mediated genes that promote oncogenesis (Roberts and
Wakefield, 2003). Thus, one sign of the conversion to
malignancy may be the ability of the cell to escape
containment from receptors that are predominantly inhibi-
tory in nature such as CD30 or TGF-b receptors.
With respect to treatment, LyP patients who are
symptomatic may be treated topically with topical steroids,
nitrogen mustard, or carmustine. Some patients with mild
CD30þ lymphoproliferative disease do not need active
treatment, but should still be observed periodically for the
development of cutaneous T cell lymphoma. Patients
with either moderate to severe forms of LyP or systemic
ALCL require treatment with MTX, bexarotene, or other
systemic agents (Krathen et al, 2003). Recurrence with any
of these agents, however, is common. For primary
cutaneous ALCL, radiotherapy and local excision are
generally very effective.
The expression of CD30 by atypical T cells (LyP and
ALCL) and B cells (Hodgkin’s disease) affords an opportu-
nity to target CD30 itself specifically. Since CD30 is not
found on most normal tissues outside the immune system
or on resting monocytes and lymphocytes, it makes an ideal
target for immunotherapy. Huhn et al (2001) have developed
an immunotoxin composed of human angiogenin fused to
human CD30 ligand that is specifically cytotoxic to CD30þ
cells in vitro. Other possible treatments include chimeric
Figure 1
Hypothetical model for negative and po-
sitive regulation of CD30þ lymphoproli-
ferative disease via CD30 and other
signaling receptors, modified from (Levi
et al, 2000). In LyP and cutaneous ALCL,
engagement of several receptors, includ-
ing CD30, Fas, and TGF-b, generally leads
to decreased cellular proliferation or even
apoptosis, which may account for clini-
cally regressive behavior of LyP and the
ease with which primary cutaneous ALCL
responds to radiotherapy. It is possible
that activation of CD30 leads to down-
regulation of TRAF proteins, increasing
susceptibility to other death signals such
as Fas. In progressive ALCL or systemic
ALCL, the malignant cells no longer
respond to negative regulators of cell
growth such as TGF-b, and may even
demonstrate proliferation to others such
as CD30 (perhaps through the ability to
upregulate NF-kB).
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antibodies against CD30 that are conjugated to cytotoxic
drugs (i.e., monomethyl auristatin E) (Francisco et al, 2003)
or a novel bispecific protein molecule that binds to both
CD30 (for specificity) and CD64/FcgR1 (to trigger Fc-
dependent killing by a variety of effector cells) (Borchmann
et al, 2002), which has already shown some efficacy in
clinical trials (Borchmann et al, 2002).
Although most experimental immunotherapies have
targeted CD30þ cells in the setting of Hodgkin’s disease,
such treatments have a potential role for controlling CD30þ
lymphoproliferative diseases. Because CD30 is likely to be a
negative regulator of T cells in LyP and can trigger apoptosis
when bound, it is possible that binding of unconjugated
CD30L or CD30-specific antibodies may induce regression
of LyP or early ALCL lesions. It should be cautioned,
however, that CD30 activation by therapeutic agents may
have different effects in systemic versus cutaneous forms of
CD30þ lymphoproliferative disorders. As our understanding
of CD30 continues to evolve, treatments that target down-
stream effectors can be developed. This ultimately will lead
to more selective, and, potentially, more effective agents
that trigger apoptosis of atypical CD30þ cells in the skin
and blood of patients with CD30þ lymphoproliferative
diseases.
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